News from novartis pharmaceuticals corporation A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 24, 2015, 19:07 ET

FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia

Novartis announced today that the US Food and Drug Administration (FDA) has approved an expanded use for Promacta® (eltrombopag) to include...

Jul 07, 2015, 16:50 ET

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan)

Novartis announced today that the US Food and Drug Administration (FDA) has approved Entresto™ (sacubitril/valsartan) tablets, previously...

Jun 11, 2015, 18:31 ET

Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder

Novartis announced today that the US Food and Drug Administration (FDA) has approved Promacta® (eltrombopag) for the treatment of children six...

Jun 01, 2015, 16:07 ET

Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma

 Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell...

Jun 01, 2015, 09:00 ET

Novartis presents new data at ASCO for Zykadia™ and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs

 Novartis today announced new data from two Phase II studies of Zykadia™ (ceritinib), as well as one Phase II study of Tafinlar®...

May 31, 2015, 10:46 ET

Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K...

May 27, 2015, 09:05 ET

Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA

 Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185...

May 20, 2015, 11:45 ET

Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies

Today, Novartis announced for the first time detailed results from its phase III EXPEDITION trial program for QVA149...

Apr 24, 2015, 06:15 ET

Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list

 Novartis Pharmaceuticals Corporation (NPC) has been named the top company for diversity for the second year in a row on the annual...

Mar 31, 2015, 13:20 ET

Novartis announces FDA approval for Jadenu(TM) to simplify treatment administration for patients with chronic iron overload

 Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral...

Feb 13, 2015, 11:32 ET

Novartis' heart failure medicine LCZ696 granted FDA priority review

 Novartis announced today that the US Food and Drug Administration (FDA) has granted priority review for LCZ696, an investigational medicine...

Jan 21, 2015, 13:29 ET

Novartis announces FDA approval for first IL-17A antagonist Cosentyx™ (secukinumab) for moderate-to-severe plaque psoriasis patients

Novartis today announced the US Food and Drug Administration (FDA) has approved Cosentyx™ (secukinumab) for the treatment of...

Dec 16, 2014, 08:00 ET

Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder

 Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor® long-acting release (LAR)* (pasireotide)...

Dec 09, 2014, 13:37 ET

Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia

 Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in...

Dec 02, 2014, 01:15 ET

Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014

 Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of...

Nov 17, 2014, 16:47 ET

Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients

 New data on Novartis' investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction (HFrEF) shows it has...

Nov 16, 2014, 14:37 ET

Novartis first IL-17A Phase III results show AIN457 (secukinumab) significantly improves psoriatic arthritis in patients

    Novartis announced today results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies showing AIN457...

Nov 15, 2014, 16:50 ET

Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies

 Novartis announced today results from the MEASURE 1 and MEASURE 2 pivotal Phase III studies of AIN457 (secukinumab) in ankylosing spondylitis...

Nov 10, 2014, 07:00 ET

Novartis to present first IL-17A Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014

 Novartis announced today that data from two pivotal Phase III studies (FUTURE 1 and FUTURE 2) in psoriatic arthritis (PsA) patients and two...

Nov 03, 2014, 09:00 ET

US results from first global survey of neuroendocrine tumor (NET) patients reveal profound impact of this rare cancer on quality of life

 Novartis together with the Carcinoid Cancer Foundation and the Caring for Carcinoid Foundation, member organizations of the International...